Signant Health Brings eConsent Solution to China

Signant Health (formerly CRF Health and Bracket), a patient-centric technology company, has been selected to provide electronic informed consent for a significant neuroscience study by the Shanghai Mental Health Center (SMHC). This investigator-led Schizophrenia trial, which will enroll hundreds of patients at multiple sites, will implement Signant’s TrialConsent solution in China. SMHC is an affiliate of Shanghai Jiao Tong University, one of the most elite research universities in the world, and a leading organization on mental health prevention planning.

Using multimedia videos, knowledge quizzes, self-paced content review, and other patient-centric eConsent capabilities, TrialConsent will help people considering enrolling in the trial-and their families-understand expectations, risks, and benefits in order to make an educated participation decision. This means patients will be more engaged with sites from the beginning, which supports patient retention throughout the study. At the same time, SMHC will benefit from a collaborative consent design process with IRBs and other stakeholders, real-time review of incoming patient consent and compliance data, and automated document management to prevent most consent-related audit findings.

Dr. Shen, Associate Professor and Vice Director of medical psychology in the Mental Health Department at Shanghai Jiaotong University, and Vice Director of the Department of Psychology at the Shanghai Mental Health Center, said,  “Signant Health, with global operations across thousands of sites, was selected for its pioneering patient facing clinical trial technologies, for understanding the unique needs of clinical trials in Asia-Pacific, and most notably proven scientific capabilities across the complex field of neuroscience. SMHC was confident Signant could support the large-scale investigator led study involving several hundred subjects across numerous hospital sites, generating significant data.”